A First-In-Class TWIST1 Inhibitor With Activity in Oncogene-Driven Lung Cancer

Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-17-0298
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2016English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology
OncologyPharmacology
2019English

A Novel Imidazopyridine PI3K Inhibitor With Anticancer Activity in Non-Small Cell Lung Cancer Cells

Oncology Reports
MedicineCancer ResearchOncology
2013English

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First‐Line Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

P53-Suppressed Oncogene TET1 Prevents Cellular Aging in Lung Cancer

Cancer Research
Cancer ResearchOncology
2019English

A Novel Dual PI3Kα/mTOR Inhibitor PI-103 With High Antitumor Activity in Non-Small Cell Lung Cancer Cells

International Journal of Molecular Medicine
MedicineGenetics
2009English

Anti-Tumour Activity of a First-In-Class Agent NUC-1031 in Patients With Advanced Cancer: Results of a Phase I Study

British Journal of Cancer
Cancer ResearchOncology
2018English

Genomic Profiling Identifies TITF1 as a Lineage-Specific Oncogene Amplified in Lung Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2008English

Methylation of the TWIST1 Promoter, TWIST1 mRNA Levels, and Immunohistochemical Expression of TWIST1 in Breast Cancer

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy